CL2009002017A1 - Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. - Google Patents
Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.Info
- Publication number
- CL2009002017A1 CL2009002017A1 CL2009002017A CL2009002017A CL2009002017A1 CL 2009002017 A1 CL2009002017 A1 CL 2009002017A1 CL 2009002017 A CL2009002017 A CL 2009002017A CL 2009002017 A CL2009002017 A CL 2009002017A CL 2009002017 A1 CL2009002017 A1 CL 2009002017A1
- Authority
- CL
- Chile
- Prior art keywords
- agonist
- aminopropanediol
- sphingosine
- phosphate
- cerebral malaria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso de monoaminas para el tratamiento de la malaria cerebral, agonistas del receptor s1p; composición farmacéutica que la comprende.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10999108P | 2008-10-31 | 2008-10-31 | |
US22997009P | 2009-07-30 | 2009-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009002017A1 true CL2009002017A1 (es) | 2011-01-07 |
Family
ID=41621568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009002017A CL2009002017A1 (es) | 2008-10-31 | 2009-10-30 | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100112037A1 (es) |
EP (1) | EP2349334A1 (es) |
JP (1) | JP2012507546A (es) |
CN (1) | CN102196820A (es) |
AR (1) | AR074062A1 (es) |
AU (1) | AU2009308843A1 (es) |
CA (1) | CA2741546A1 (es) |
CL (1) | CL2009002017A1 (es) |
PE (1) | PE20100371A1 (es) |
TW (1) | TW201021790A (es) |
UY (1) | UY32214A (es) |
WO (1) | WO2010051349A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159864A1 (en) * | 2010-06-17 | 2011-12-22 | Bracco Imaging S.P.A. | Jte013 analogs and methods of making and using same |
EP2643331A1 (en) | 2010-11-22 | 2013-10-02 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
KR101820330B1 (ko) * | 2013-10-11 | 2018-01-19 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법 |
JP6618191B2 (ja) * | 2014-03-27 | 2019-12-11 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 脳マラリアの診断および治療 |
EP3474831A1 (en) | 2016-06-23 | 2019-05-01 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
WO2018022814A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
MX2019001104A (es) | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
KR20230109782A (ko) | 2016-07-27 | 2023-07-20 | 코리움, 엘엘씨 | 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된경피성 전달 |
US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
EP3810274A4 (en) * | 2018-06-21 | 2022-03-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | COMBINATION OF FINGOLIMOD AND AT LEAST ONE ANTI-PILEPTIC |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0155015B1 (ko) * | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
EP1663188B1 (en) * | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Treatment of disorders of the nervous system |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
MY146775A (en) * | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
TW200838497A (en) * | 2006-12-21 | 2008-10-01 | Abbott Lab | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
AR065980A1 (es) * | 2007-04-12 | 2009-07-15 | Lexicon Pharmaceuticals Inc | Metodos para preparar compuestos basados en imidazol |
TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
-
2009
- 2009-10-28 AR ARP090104143A patent/AR074062A1/es unknown
- 2009-10-28 PE PE2009001210A patent/PE20100371A1/es not_active Application Discontinuation
- 2009-10-29 CN CN2009801429488A patent/CN102196820A/zh active Pending
- 2009-10-29 WO PCT/US2009/062502 patent/WO2010051349A1/en active Application Filing
- 2009-10-29 JP JP2011534744A patent/JP2012507546A/ja active Pending
- 2009-10-29 CA CA2741546A patent/CA2741546A1/en not_active Abandoned
- 2009-10-29 EP EP09752585A patent/EP2349334A1/en not_active Withdrawn
- 2009-10-29 US US12/608,332 patent/US20100112037A1/en not_active Abandoned
- 2009-10-29 AU AU2009308843A patent/AU2009308843A1/en not_active Abandoned
- 2009-10-30 TW TW098136956A patent/TW201021790A/zh unknown
- 2009-10-30 CL CL2009002017A patent/CL2009002017A1/es unknown
- 2009-10-30 UY UY0001032214A patent/UY32214A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2009308843A1 (en) | 2010-05-06 |
CN102196820A (zh) | 2011-09-21 |
WO2010051349A1 (en) | 2010-05-06 |
AR074062A1 (es) | 2010-12-22 |
PE20100371A1 (es) | 2010-06-01 |
US20100112037A1 (en) | 2010-05-06 |
UY32214A (es) | 2010-05-31 |
CA2741546A1 (en) | 2010-05-06 |
EP2349334A1 (en) | 2011-08-03 |
JP2012507546A (ja) | 2012-03-29 |
TW201021790A (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
DOP2009000237A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingosina 1-fosfato (s1p) | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
UY31570A1 (es) | Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos | |
DOP2012000051A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
GT201400261A (es) | Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
CO6390117A2 (es) | Regimen de dosificación para un agonista de los receptores de s1p | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
CR20120012A (es) | Agonistas de gpr119 | |
CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
CL2011000184A1 (es) | Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos. |